Free Recommendation
Leads to 18% Gain in 1 Month
10/18/03
On September 14 we publicly released our recommendation to
buy INAMED Corp. Since then, the company is up 18% while the
stock market is only up 2%. In fact, readers who have created
a portfolio from all of the stocks we rate as an "A-"
or higher in our free "Industry Analysis" articles
are also beating the market.
Last Thursday alone the company rose 23%
on news an FDA advisory panel recommends approval for one
of their products. More information follows in the company's
press release:
FDA Advisory Panel Recommends Approval
of INAMED's Gel-Filled Breast Implants
Santa Barbara, Calif.,
October 15, 2003 - INAMED Corporation (Nasdaq: IMDC), a global
healthcare company, today announced that the General and Plastic
Surgery Advisory Panel of the U.S. Food and Drug Administration
(FDA) recommended, with conditions, approval of the Company's
premarket approval (PMA) application to market gel-filled
breast implants in the United States. The Panel voted that
the FDA should approve, with conditions, INAMED's gel-filled
breast implants for all indications -- breast augmentation,
reconstruction and revision.
"This positive recommendation by the
Advisory Panel is an important decision for the many women
who seek more options when considering reconstruction, augmentation
or revision surgery," said Nick Teti, Chairman, President
and Chief Executive Officer of INAMED Corporation. "We
look forward to working with the FDA during the next step
of this process."
In connection with the recommendation, the
Panel voted to adopt several conditions designed to address
issues relating to patient follow-up, patient informed consent
and surgeon education/verification, among other issues.
INAMED manufactures and sells gel-filled
implants internationally in more than 60 countries. For more
than a decade, gel-filled implants in the U.S. have been restricted
to patients undergoing reconstruction or revision surgery
and who are also participating in clinical studies. If the
panel's recommendation is adopted by the FDA, Teti added,
"The same choices that are available to women in 60 countries
worldwide we hope will soon be available to women in America."
About INAMED Corporation
INAMED (Nasdaq: IMDC) is a global healthcare company with over
25 years of experience developing, manufacturing and marketing
innovative, high-quality, science-based products. These products
include breast implants for aesthetic augmentation and for reconstructive
surgery; a range of dermal products to treat facial wrinkles;
and minimally invasive devices for obesity intervention, including
the LAP-BAND® System for morbid obesity. The Company's web
site is www.inamed.com.
Forward-Looking Statements
This press release contains, in addition to historical information,
forward-looking statements. Such statements are based on management's
current estimates and expectations and are subject
to a number of uncertainties and risks that
could cause actual results to differ or differ materially
from those described in the forward-looking statements. INAMED
is providing this information as of October 15, 2003 and expressly
disclaims any duty to update information contained in this
press release.
This press release contains additional forward-looking
statements, including, without limitation, consideration of
INAMED's silicone gel-filled breast implant pre-market approval
(PMA) application at an FDA Advisory Panel meeting held on
October 14 and 15, 2003 and INAMED's anticipated product development
program. These forward-looking statements involve risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied here. Readers are
referred to the documents filed by INAMED with the Securities
and Exchange Commission, specifically the most recent reports
which identify important risk factors that could cause actual
results to differ from those contained in the forward-looking
statements.
The information contained in this press
release is a statement of INAMED's present intention, belief
or expectation and is based upon, among other things, the
existing regulatory environment, industry conditions, market
conditions and prices, the economy in general and INAMED's
assumptions. INAMED may change its intention, belief or expectation,
at any time and without notice, based upon any changes in
such factors, assumptions or otherwise. INAMED undertakes
no obligation to review or confirm analysts' expectations
or estimates or to state publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
By including any information in this press
release, INAMED does not necessarily acknowledge that disclosure
of such information is required by applicable law or that
the information is material.
INAMED Contact:
Robert S. Vaters
INAMED Corporation
(805)692-5420
INAMED Media Contact:
Rod Young or Rebecca Smith
McGinn Group
(703) 312-0147
INAMED Corporation
5540 Ekwill Street
Santa Barbara, CA 93111
(805) 692-5400 Telephone
(805) 692-5432 Facsimile
|
